Rein Therapeutics reports preliminary blinded Phase 2 RENEW data in idiopathic pulmonary fibrosis
Pooled, blinded data from 24 evaluable patients showed 33% improved in forced vital capacity at Week 12, though the results do not establish a treatment effect.